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Abstract
The tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine playing a key role in tissue
regeneration and remodeling. Dysregulation of TWEAK signaling is involved in various pathological processes like
autoimmune diseases and cancer. The unique interaction with its cognate receptor Fn14 makes both ligand and receptor
promising targets for novel therapeutics. To gain insights into this important signaling pathway, we determined the
structure of soluble human TWEAK in complex with the Fab fragment of an antibody selected for inhibition of receptor
binding. In the crystallized complex TWEAK is bound by three Fab fragments of the neutralizing antibody. Homology
modeling shows that Fab binding overlaps with the putative Fn14 binding site of TWEAK. Docking of the Fn14 cysteine rich
domain (CRD) to that site generates a highly complementary interface with perfectly opposing charged and hydrophobic
residues. Taken together the presented structure provides new insights into the biology of TWEAK and the TWEAK/Fn14
pathway, which will help to optimize the therapeutic strategy for treatment of related cancer types and autoimmune
diseases.
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Introduction
The TNF-like weak inducer of apoptosis (TWEAK, TNSF12,
APO3L, CD255) is a member of the TNF superfamily of
cytokines. TWEAK was first described in 1997 as a novel TNF-
like protein displaying pro-apoptotic activity on interferon c
treated human HT-29 colon carcinoma cells [1] and since then
has emerged as a prominent player in normal and pathological
tissue remodeling. It is expressed as a 249 amino acid long type II
membrane bound protein and comprises an intracellular N-
terminal domain, which contains a potential protein kinase C
phosphorylation site, a transmembrane domain and an extracel-
lular TNF homology domain (THD). Upon specific proteolysis by
the serine protease furin, soluble TWEAK is released from
membranes [1–3].
Both membrane bound and soluble forms of TWEAK have
been shown to be able to bind to the TWEAK receptor and trigger
signaling [2]. The cognate TWEAK receptor (Fn14, TWEAKR,
TNFRSF12A, CD266) is the smallest member of the TNF
receptor superfamily (TNFRS) so far and interacts only with
TWEAK [4]. The extracellular TWEAK binding domain of Fn14
comprises a single cysteine rich domain (CRD) that contains 3
disulfide bonds. It is structurally related to the CRD of other
TNFRS members, some of which have been structurally
characterized [5].
Signaling of Fn14 is initiated when TWEAK binds to the
receptor and induces its trimerization. The signal is transmitted
into the cell by attraction of the TNFR-associated factors (TRAFs)
1, 2, 3 and 5 to the short C-terminal cytoplasmic tail of Fn14 [6,7].
This interaction leads to the activation of several signaling
pathways including the ERK [8–10] and JNK [8,11] pathways
as well as the non-canonical [12–14] and canonical NF-kB
signaling cascade [6,7,13–16]. The activation of the pathways
results in the induction or repression of target gene expression.
Since its discovery, the TWEAK-Fn14 cytokine-receptor system
has emerged from a weakly apoptosis-inducing signal to a key-
player in the regulation of various, sometimes even opposing,
cellular processes in tissue remodeling. Presence of TWEAK was
shown in vitro to stimulate or inhibit proliferation, initiate or
prohibit differentiation, support migration, prolong survival or
induce cell death [1,17–22]. Additionally, Maecker and colleagues
revealed that TWEAK serves as a regulator of the innate immune
system and its interplay with adaptive immunity. [23] The
biological relevance of TWEAK is potentiated by the fact that
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in contrast to other TNF superfamily members TWEAK is a
widely expressed cytokine in many different tissue and tumor
specimens (for references see [24]). Its receptor Fn14 is expressed
in all cell types analyzed so far, except primary B and T cells. In
contrast to other TNFRS members, Fn14 expression is up-
regulated by a wide range of cytokines, growth factors and Fn14
self-activation [8,25,26]. The large repertoire of cellular responses
together with the broad range of cell types expressing TWEAK
and Fn14 makes them key regulators of progenitor expansion, cell
proliferation, cell migration, angiogenesis and inflammation
during tissue repair after acute injuries and in physiological tissue
remodeling [4,8,27–34].
All these processes have to be tightly regulated and any
dissonance in this orchestra easily leads to pathological effects.
Consequently, the TWEAK-Fn14 axis was shown to play a
detrimental role in several diseases. The ambivalent nature of
TWEAK signaling is reflected in its effects on tumors. On the one
hand, TWEAK is indeed able to induce apoptosis in tumor cells
[35]. On the other hand, Fn14 expression is up-regulated in many
tumor cell lines and tumors promoting proliferation, angiogenesis,
inflammation, cell invasion and metastasis [15,17,18,26,29,36–
41]. Imbalance in the regulation of TWEAK in the process of
inflammation and immune modulation leads to the development
of chronic inflammation and autoimmune diseases like rheuma-
toid arthritis [20,42], systemic lupus erythematosus [43,44],
neuroinflammation [16,45], multiple sclerosis [46,47] and ischae-
mic stroke [48–51]. The involvement of the TWEAK-Fn14 axis in
beneficial as well as hazardous processes, make both ligand and
receptor potential targets for novel therapeutics.
Possible new therapeutic approaches based on monoclonal
antibodies or antibody derivates can either directly block the
TWEAK Fn14 interaction or kill the cells by targeting Fn14 with
antibodies inducing Antibody-dependent cell-mediated cytotoxic-
ity (ADCC), delivering toxins or triggering the intrinsic apoptotic
potential of Fn14. However, no structural information of this
important cytokine or its interaction with Fn14 is available,
perhaps because TWEAK is a very sticky and difficult to handle
protein and not well suited for forming highly ordered crystals. In
addition, a complex of TWEAK with a potentially therapeutic
antibody could help develop treatments aimed at neutralizing the
activity of TWEAK in soluble form or in its membrane bound
form. In this study we report the crystal structure of TWEAK in
complex with a Fab derived from a humanized neutralizing anti-
TWEAK rabbit antibody. We derive a molecular framework for
TWEAK, differences and similarities to other TNF family
cytokines and, by comparison with available structures of TNF
superfamily members in complex with their receptors, our
structure enables us to dock the Fn14 CRD to its putative binding
site on the ligand TWEAK. In addition, the structure of human
TWEAK suggests that binding to HSPGs is important for
triggering signaling after acute injuries and supports tumor
development as it is observed for other cytokines.
Materials and Methods
Half-Life Determination of the TWEAK-antibody Complex
A Biacore 2000 instrument was used with a Biacore SA and
HBS-ET (10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA,
0.05% TweenH 20). Biotinylated human soluble TWEAK was
coupled to the chip at 150 RU. Antibodies (100 mM in HBS-ET)
were injected at 100 nM with a flowrate of 100 ml/min for 2 min
association time. The dissociation of the immune complex was
monitored for 5 min at 25uC in HBS-ET. The kinetically rate
limiting step of the complex dissociation phase in the interval
[240 s–300 s] was taken to calculate the dissociation rate kd [1/s]
(Biacore Evaluation Software 4.0). According to the equation t1/2
diss = ln(2)/(606kd), the half-life of the immune complex in
minutes was calculated.
Crossblocking Experiment
A Biacore 3000 instrument was used at 25uC with a Biacore SA
sensor and HBS-ET as system buffer (10 mM HEPES pH 7.4,
150 mM NaCl, 1 mM EDTA, 0.05% TweenH 20). The sensor
was treated with EDC/NHS chemistry (Biacore) and blocked with
ethanolamine to suppress unspecific binding. Finally, the sensor
was conditioned with 361 min 1 M NaCl/50 mM NaOH and
161 min 10 mM HCl at 100 ml/min. The biotinylated TWEAK
ligand was injected at 5 nM in HBS-ET at a flow rate of 30 ml/
min over all flow cells. Subsequently the respective primary
antibody was injected in a single flow cell at 10 ml/min for 4 min.
The secondary antibody was injected over all flow cells with the
same conditions as the primary antibody. The binding level of the
primary and secondary antibody was monitored and the Molar
Ratio (MR) was calculated as the quotient from the signal level of
secondary antibody/primary antibody. The sensor was inactivated
by a 1 min injection at 30 ml/min of 6 M guanidinium
hydrochloride in 100 mM glycine buffer pH 1.5. The TWEAK
ligand was inactivated. The baseline was stabilized by a 7 min
injection of HBS-ET at 100 ml/min. Within 7 cycles, new
biotinylated TWEAK ligand was captured in the flow cells at
294 RU +/25 RU. As a control, 100 nM polyclonal sheep
antibody (Roche) was injected instead of primary and secondary
antibody.
Neutralization of TWEAK-Fn14 Interaction
Blocking of TWEAK-Fn14 interaction was shown by receptor
interaction ELISA. 96-well MaxisorpH plates (Nunc, Langensel-
bold, Germany) were coated with 100 ml 1 mg/ml human Fn14:Fc
(extracellular domain of human Fn14 (amino acids 1–75) fused to
Fc portion of human IgG1) in PBS per well for 1.5 h at room
temperature and blocked with a solution of 5% FBS in PBS for 30
minutes at room temperature under shaking. In the meantime,
human Flag-tagged soluble TWEAK (amino acids 106–249;
2.5 ng/ml in blocking solution) was incubated with different
concentrations of anti-TWEAK antibody or hybridoma superna-
tant for 2 h at room temperature under shaking. After washing the
Fn14-coated plate once with buffer (0.1% TweenH 20 in PBS),
100 ml of the TWEAK-antibody solution were transferred to each
well and the plate was incubated for 1 h at room temperature,
followed by four washes with wash buffer. Wells were filled with
100 ml of anti-FLAG-HRP detection antibody, diluted 1:5000 in
blocking buffer, and incubated for 1 h at room temperature. After
four more wash steps, the signal was developed by addition of
100 ml 3,3,5,5-Tetramethylbenzidine (TMB) solution for approx-
imately ten minutes. The reaction was stopped by adding 100 ml of
1 N 10 HCl, and absorbance measured at 450 nm (reference
wavelength 620 nm).
IL-8 Secretion ELISA
Blocking of TWEAK activity by the anti-TWEAK antibody in a
cellular system was shown in an IL-8 secretion assay using A375
melanoma cells. 10,000 A375 cells (ATCC #CRL1619) were
seeded per well of 96-well cell culture plate in 100 ml of growth
medium (DMEM with 4.5 g/L glucose, with pyruvate and
GlutaMAXTM/10% FBS) and incubated at 37uC/5% CO2 for
48 h. Human recombinant soluble TWEAK was pre-incubated at
300 ng/ml with different concentrations of anti-TWEAK anti-
bodies in growth medium for 30 minutes at room temperature.
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Then, 50 ml of the mixture were added to each well of the cell
plate, followed by another 48 h-incubation to allow for IL-8
secretion. 20 ml of the cell supernatant were removed after
centrifuging the plate for five minutes at 2006g and mixed with
980 ml of RD5P Calibrator Diluent from the ‘‘CXCL8 Quantikine
ELISA’’ kit (R&D Systems). IL-8 was detected by the ELISA
according to the manufacturer’s instructions.
Protein Production and Crystallization
Chimeric rabbit anti-TWEAK monoclonal antibody was
produced by standard procedures. A Fab fragment was prepared
by papain digestion for 3 h. The Fc portion was removed using a
HiTrap MabSelect Xtra column (GE Healthcare, Munich,
Germany) and the Fab fragment purified by gelfiltration on a
Sephadex 75 column (GE Healthcare, Munich, Germany) with
20 mM His-HCl, 140 mM NaCl, pH 6.0 as buffer. For complex
formation of the Fab with human TWEAK, the Fab solution was
used to directly dissolve freeze-dried recombinant human
TWEAK (PeproTech GmbH, Hamburg, Germany) to a final
molar ratio of 1:1. To remove residual phosphate from the
TWEAK preparation, the complex was desalted with 5 ml
HiTrap Desalting columns (GE Healthcare, Munich, Germany)
and 20 mM His-HCl, 140 mM NaCl, pH 6.0 as buffer. For
crystallization, 1 ml protein solution (18 mg/ml) was mixed with
1 ml reservoir solution 30% w/v Ethanol/10% w/v PEG6000/
100 mM Sodium Acetate. Crystals grew at 25uC using the
hanging drop vapor diffusion method. Prior to flash freezing in
liquid nitrogen, crystals were cryoprotected by adding 1 ml
reservoir supplemented with 20% (v/v) 1,4-butanediol to the drop.
Data Collection, Molecular Replacement and Structure
Refinement
Diffraction Data were recorded at 100 K at the beamline
X06SA (SLS/Switzerland) and processed with XDS [52] (Table 1).
Initial phases were obtained by molecular replacement with
PHASER [53] using the previously solved structure of a
therapeutic antibody Fab fragment in complex with human
TWEAK as search models (to be published). In total, one complex
consisting of one Fab fragment and one TWEAK molecule could
be positioned in the asymmetric unit. The complete biological
relevant complex of a TWEAK trimer bound by three Fab
fragments can be generated by applying three fold symmetry along
the crystallographic axis. Initial models were completed and
refined by iterative cycles of manual model building including
water placement with COOT [54] and standard crystallographic
refinement including positional refinement, bulk solvent correc-
tion, overall anisotropic B factor and TLS refinement with Phenix
[55]. In the final refinement round of a twinned refinement with
Phenix [56] using the twin law -k,-h,-l has been applied.
Refinement and model statistics are shown in Table 2. Buried
surfaces were calculated with AreaIMol [57]. Rigid body and
positional refinement of the putative TWEAK-Fn14 complex was
performed with CNS [58]. Structure figures were generated with
PyMOL (www.pymol.org).
Results
Structure Determination of the TWEAK-Fab Complex
Anti-human TWEAK antibodies were obtained by immuniza-
tion of New Zealand white rabbits and selected for their ability to
bind human TWEAK, neutralize TWEAK-Fn14 interaction and
inhibit TWEAK-induced IL-8 secretion in A375 melanoma cells.
From all binders, three showed inhibition of the TWEAK-Fn14
interaction with IC50 in the low nM range resulting in the
reduction of IL-8 secretion with an IC50 around 700 nM (Table 3).
To test whether the selected antibodies bind different epitopes
we performed crossblocking experiments using surface plasmon
resonance. The accessibility values of all tested antibodies are
below 10%, which is in the noise of the assay. These data indicate
that the tested antibodies bind to overlapping epitope regions
(Table 2). For crystallization, the antibody forming the immune
complex with the slowest koff was chosen (TW305chi in Table 3).
Table 1. Crystallographic data collection and model
refinement statistics.
Data collection
Beamline X06SA (SLS)
Wavelength 0.933
Space group Unit Cell parameters P3
a, b, c (A˚) 101.64 101.64 57.59
a, b, c (u) 90 90 120
Resolution (A˚) (last shell) 30.0–2.5 (2.65–2.50)
Observed reflections (last shell) 84796 (13268)
Completeness (last shell) 99.5 (97.8)
Redundancy (last shell) 3.7 (3.7)
Rsym (last shell) 9.8 (15.8)
I/s (last shell) 3.7 (3.7)
Refinement
Resolution (A˚) 30–2.5
No. reflections (test) 22932 (2294)
Rwork/Rfree 18.34/21.11
No. atoms
Protein 4273
Water 100
rmsd from ideal
Bond lengths (A˚) 0.013
Bond angles (u) 1.625
Ramachandran plot
Most favoured (%) 95.8
Additionally allowed (%) 4.02
Disallowed (%) 0.18
PDB Accession Code 4HT1
doi:10.1371/journal.pone.0062697.t001
Table 2. Cross blocking assay.
Molar Ratio1 (%) Antibody 2
Antibody 1 chi TW-301 chi TW-304 chi TW-305
chi TW-301 0 6 9
chi TW-304 0 0 3
chi TW-305 0 1 0
1The Molar Ratio (MR %) was calculated as the quotient of the secondary
antibody binding signal to the primary antibody binding signal, both binding to
the surface-presented TWEAK ligand.
doi:10.1371/journal.pone.0062697.t002
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From this antibody, Fab fragments were produced and used for
crystallization of a complex between human TWEAK and the Fab
fragments.
The complex of soluble human TWEAK with the Fab fragment
was reconstituted by directly dissolving lyophilized recombinant
soluble human TWEAK in the buffer containing the Fab. In
contrast to TWEAK alone, the reconstituted complex can easily
be desalted without the reported problems of protein sticking to
size exclusion matrices under low salt conditions [1]. The structure
of the complex was solved by molecular replacement with a
limiting resolution of 2.5 A˚ and refined to an R-factor of 23.8%
(Rfree = 28.4%). Examples of initial 2mFo-DFc electron density
after replacement and final 2mFo-DFc density after coordinate
refinement are shown in Figures 1C and D respectively. Complete
crystallographic statistics are summarized in Table 1.
In total, one TWEAK molecule and one Fab fragment could be
positioned in the asymmetric unit. Like other members of the TNF
superfamily, soluble TWEAK is a homotrimer. This biological
relevant trimer is found in the crystal and can be generated by
applying the symmetry operation of the 3-fold crystallographic axis
that coincides with the intrinsic 3-fold axis of the TWEAK trimer
(Fig. 1A). The immune complex consists of one TWEAK
homotrimer with three bound Fab fragments. When viewed along
the 3-fold axis the hexameric complex has an overall shape that
resembles a three-bladed propeller with each TWEAK-Fab
protomer being one blade (Fig. 1A).
The pseudo 2-fold axis of the Fab fragments relating the heavy
and light chains is not perpendicular to the 3-fold axis but the Fab
fragments are tilted , 45u out of the plane (Fig. 1B). The 3-
dimensional arrangement of the hexameric complex resembles
therefore a trigonal pyramid with the TWEAK trimer at the apex
and the three Fab fragments pointing towards the 3 corners of the
trigonal base (Fig. 1B). In this binding orientation the antibody
would point away from the membrane in the situation of the
membrane bound TWEAK precursor, with the membrane located
above the TWEAK molecule in Figure 1B. Thereby the antibody
not only binds soluble TWEAK, but in principle might be able to
bind to TWEAK before it is released from its membrane bound
Table 3. Biochemical analysis of selected anti TWEAK antibodies.
Inhibition of TWEAK-FN14 interaction Half-life of immunocomplex Inhibition of IL-8 secretion
IC50 [ng/ml] t/2 diss [min] IC50 [ng/ml]
TW-301 3.4 n.d. 128
TW-304 2.8 n.d. 109
TW-305 2.5 n.d. 99
chi TW-301 2.8 110 121
chi TW-304 2.6 37 122
chi TW-305 2.6 147 104
doi:10.1371/journal.pone.0062697.t003
Figure 1. Overall structure of the TWEAK - Fab complex. A) Ribbon model of human TWEAK (orange) complexed with the Fab fragment of a
therapeutic antibody (light chain in blue and heavy chain in green). The symmetry related two TWEAK – Fab complexes forming the physiological
trimeric TWEAK are colored in gray with the corresponding 3-fold crystallographic axis depicted as a black triangle. The complex resembles a three-
bladed propeller with each TWEAK-Fab protomer being one blade. B) Side view of the complex with same colors as in A. The Fab fragments are not
binding planar but tilted , 45u out of the plane to TWEAK leading to a trihedral shaped complex. C) Initial 2FoFc electron density after replacement
as blue mesh around the disulfide bond of human TWEAK contoured at 1s (amino acids as color coded sticks). D) Final 2FoFc electron density after
refinement as blue mesh around the disulfide bond of human TWEAK contoured at 1s (amino acids as color coded sticks).
doi:10.1371/journal.pone.0062697.g001
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precursor. On the one hand, the antibody can neutralize soluble
TWEAK molecules. On the other hand, the antibody might be
able to inhibit direct signaling of membrane bound TWEAK.
Details of the TWEAK-Fab Interface
The Fab binds to a non-linear epitope on human TWEAK. The
recognition of the epitope is mainly achieved by the hypervariable
region of the heavy chain. Notable hydrogen bonds involved in the
binding are YH33–GT185 (3.4 A˚) of CDR H1, QH55 - DT184 (3.1 A˚)
and RH54 - ET152 (3.3 A˚) of CDR H2 and YH101–IT150 (3.2 A˚),
YH103–GT185 (2.7 A˚), DH104–RT227 (2.8 A˚) of CDR H3. From the
light chain, a hydrogen bond is formed between YL93 of CDR L3
and LT187 (2.7 A˚) (Fig. 2C). In addition to the hydrogen bonds, a
central p stacking interaction between YH101 and RT225 supports
the specificity towards the epitope (Fig. 2C). The residues of
TWEAK forming the antigenic epitope are located in the loops
connecting strands D/E and B’/B and residues of strand G (for
numbering see Fig. 3C). The interaction of the Fab fragment with
TWEAK buries in total an area of 882 A˚2, which is in the typical
range of the interaction surface between antibodies and protein
antigens [59]. Besides this main antigen-antibody recognition, an
additional interaction between residues RL68 located in a loop on
one of the six canonical CDR loops and DT265 of a second
TWEAK molecule of the TWEAK trimer is formed (Fig. 2C).
However, both residues are located outside the core epitope and
are solvent exposed. As a result of that exceptional position, the
arginine can be mutated in the process of humanization to glycine
without loss of affinity.
Details of the TWEAK-TWEAK Interfaces
The biological relevant complex displays a 1:1 stoichiometry.
The epitope important for binding and specificity is located within
a single TWEAK protomer and the Fabs do not bridge protomers
in the trimer. The TWEAK protomer adopts the typical THD fold
with a central sandwich of two five-stranded antiparallel b-strands
with a smaller two-stranded one flanking them (Fig. 3A). The loops
and strands harboring the residues of the antigenic epitope form
part of one of the larger antiparallel b-sheets comprising strands
B’, B, G, D and E. This sheet is facing the outside of the TWEAK
trimer and is linked by a disulfide bond between residues C191 of
strand E and C210 of strand F with the second five-stranded
antiparallel b-sheet (Fig. 3A). The second sheet formed by strands
A’, A, H, C and F is located inside mainly mediating the
trimerization of TWEAK. The buried surface area between the
TWEAK protomers is approximately 800 A˚2, which is in
agreement with the numbers for interactions of proteins of that
size [60]. The interface spans almost the complete height of the
molecule. Residues belonging to strands H, C, F and loop G’-H of
one TWEAK protomer interact with residues of strands F and C
of the corresponding sheet in the other protomer. Additional
interactions are formed to strand E of the second large b-sheet as
well as to loop E-F (Fig. 3C). In total, ten hydrogen bonds are
formed in the core interface (listed in Fig. 3C). Together with some
Figure 2. Interaction of the antibody with TWEAK. A) Ribbon representation of one Fab fragment binding to one TWEAK protomer
(orange:TWEAK, blue:light chain, green:heavy chain). B) Stereo representation of the epitope recognition with interacting residues as labeled stick
model and important hydrogen bond interaction highlighted as dashed lines. The binding is mainly mediated by CDR loop 1 and 2 of the heavy chain
interacting with residues of the loops connecting strands D/E and B’/B and residues of strand G. In addition Y93 of CDR3 of the light chain interacts
with a main chain N and stacks with the guanidinium group of R130 of TWEAK. C) Interestingly not only canonical CDR loops are involved in TWEAK
binding, but an additional hydrogen bond is formed between light chain R68 of a non CDR loop with D75 of a second subunit of the trimeric TWEAK
complex (gray).
doi:10.1371/journal.pone.0062697.g002
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Figure 3. Structure of human TWEAK. A) Ribbon representations of the TWEAK trimer with one protomer colored orange and the symmetry
related ones in gray (crystallographic 3-fold axis indicated as black triangle). On the left top view oriented as in 1A with N- and C-Terminus on the top.
In the middle side view oriented as in 1B with labeled N- and C-Terminus. In the situation of the uncleaved precursor the membrane is located on top
of the molecule. The disulfide bond is highlighted as stick model and beta strands are labeled according to TNF superfamily nomenclature. The
dashed lines indicate flexible loops E-F and A-A’’ not visible in the electron density. On the right, bottom view of the TWEAK trimer. B) Solvent
accessible electrostatic surface potential (red 24 kT to blue +4 kT) of the TWEAK trimer with the same orientations as in A. Resembling the high pI of
TWEAK with 9.62 the complete upper surface is highly positively charged. A second basic patch is located at the side of the TWEAK trimer (dashed
ellipse middle picture). This positively charged region is also found in other members of the TNF family (i.e. APRIL, BAFF) and coincides with their
receptor binding site. C) Overview of the TWEAK-TWEAK interface as found in the homotrimer in the same orientation and labeled as in A (middle
picture). Notable hydrogen bonds involved in the trimerization are indicated as dashed lines with the respective interacting amino acids as sticks. The
hydrogen bonds with interacting atoms and distances are listed in the table.
doi:10.1371/journal.pone.0062697.g003
Human TWEAK Crystal Structure
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hydrophobic interactions these contacts lead to a tight self-
trimerization of TWEAK. The trimeric state is important for the
biological function as the trimerization of the Fn14 receptor upon
TWEAK binding triggers the intracellular signaling. Since the
signaling can be triggered by the membrane bound full length
TWEAK [13], it is likely that the TWEAK precursor is already
trimerized on the membrane.
TWEAK Surface Properties and Model for Fn14
Interaction
To analyze surface properties of TWEAK, we calculated the
electrostatic potential for the solvent accessible surface of the
soluble TWEAK trimer. The surface potential reveals a basic
patch located at the side of the TWEAK trimer (Fig. 3B middle
and Fig. 4A). In our structure, this region is covered by the Fab
fragment, which is derived from an antibody directed against
disrupting the TWEAK-Fn14 interaction. Thus, it is likely that the
basic patch is directly involved in the TWEAK-Fn14 interaction.
To learn more about the interaction of TWEAK with its receptor,
we first superimposed available structures of THDs in complex
with the CRDs of their receptors, in particular APRIL (a
proliferation inducing ligand) THD with BCMA (B cell matura-
tion) CRD (PDB ID 1XU2), APRIL THD with TACI (Tumor
necrosis factor receptor superfamily member 13B, also known as
TNFRSF13B) CRD (PDB ID 1XU1), TALL THD with BCMA
CRD (PDB ID 1OQD) and TALL CRD with BAFFR (receptor
for B-cell activating factor) THD (PDB ID 1OQE)]. In fact, in all
experimentally derived THD-CRD complexes, the receptors bind
the cytokine at the position of the positive patch (Fig. 4B). Using
this information, together with the NMR structure of human Fn14
CRD (PDB ID 2RPJ), we can generate a model for TWEAK-
Fn14 by superimposing the human TWEAK structure with THDs
and the NMR structure of Fn14 with the CRDs of the
experimentally determined complexes. The model of the
TWEAK-Fn14 complex is shown in Fig. 4C and can explain
receptor trimerization without any observable clashes between the
three Fn14 molecules.
To minimize energy of the complex model we used rigid body
and positional refinement with CNS [58], which resulted in a
highly complementary and specific binding interface between
TWEAK and Fn14. The buried surface area of approximately
460 A˚2 for the TWEAK-Fn14 interaction is smaller than for the
other THD-CRD complexes. However, one can expect some
rearrangements of the Fn14 molecule upon TWEAK binding
compared to the present NMR structure in solution, which might
lead to an increased interaction surface. Regardless of such
rearrangements, the highly complementary interface, with ap-
proximately ten potential hydrogen bonds between the Fn14 CRD
and TWEAK in the model, suggests a sufficiently strong receptor
cytokine interaction, in agreement with the low experimental Kd
values of , 0.8–2.4 nM. In our model, the charged side chains of
Fn14 residues D45, D47, K48, R58 and D62 recognize TWEAK
and form the dense hydrogen bond network. This is in accordance
with mutational analysis showing the importance of D45, K48 and
D62 for TWEAK binding, but e.g. S38 and P56, which do not
form direct interactions, being dispensable [61]. Thus, the model
is consistent with and can nicely explain mutagenesis data.
TWEAK Surface Properties and Model for HSPG
Interaction
A second highly positively charged area spans the top of the
TWEAK trimer (Fig. 3B left). A similar basic patch is observed for
APRIL and other related molecules of the TNF family, indicating
that this surface area is functionally important. In the case of
APRIL, this basic patch is shown to bind to negatively charged
sulphated side chains of HSPG. While binding of one soluble
APRIL trimer to the receptor is not sufficient for signaling, the
multimerization of APRIL upon interaction with the HSPGs and
thereby the oligomerization of the receptors efficiently triggers
signaling [62–66]. A similar observation was made for BAFF,
TNF, CD95L, TRAIL and recently for TWEAK [13,67–70].
Thus, consistent with these data, the positive patch on the
TWEAK molecule is well suited and a likely surface area for a
possible interaction with HSPGs.
Discussion
Research over the past years established TWEAK as a
multifunctional cytokine accompanying a key role in the various
physiological processes especially tissue regeneration and reorga-
nization [27–34]. Disregulation of the TWEAK-Fn14 cytokine
receptor axis is involved in numerous pathological events including
cancer (reviewed in [71]), chronic autoimmune diseases [20,42–
47] and acute ischaemic stroke [48–50,72]. Accordingly, TWEAK
is an interesting target in the development of antibody-based
therapies against these diseases. Although several studies addressed
the function of TWEAK and its receptor Fn14 in these processes
in vitro and in vivo, no structural information of TWEAK or its
interaction with Fn14 is available. In this study we report the
crystal structure of the soluble form of human TWEAK in
complex with the Fab fragment of a neutralizing antibody to
obtain information on the structural features of TWEAK.
The complex formation with the Fab fragment was beneficial in
several ways. The binding of the Fab fragment to human TWEAK
greatly improved the handling of the protein. Whereas the free
protein easily sticks to size exclusion matrices, the complex could
easily be desalted and concentrated in complex with the Fab. In
addition, neutralizing antibodies selected for the inhibition of
ligand-receptor binding likely bind or block this interaction and
can help determine the location of the receptor-ligand interface.
Finally, the structure helps to develop antibody-based therapies
against diseases where TWEAK is implicated. Comparison with
available structures of other TNF superfamily members in
complex with the CRD of their receptors revealed the putative
receptor binding site on TWEAK, and this binding site is exploited
and shielded by the Fab fragments. Based on this information we
could also generate a model between human TWEAK and the
Fn14 CRD that nicely explains and is supported by published
mutational studies.
The interaction between TWEAK and its receptor is in contrast
to many other TNF ligands and receptors unique [4]. This
property makes the TWEAK-Fn14 axis as therapeutic targets
especially interesting and potentially superior to other TNF family
members. The occurrence of undesired side effects might be
reduced compared to targeting ligands binding multiple receptors
or receptors accepting different ligands. The presented structure
shed light for the first time on the rather specific molecular
recognition of TWEAK by Fn14 and provides a basis for the
development and improvement of therapeutic molecules highly
specific for targeting these two proteins. Our model provides a first
glimpse into the specific interaction of TWEAK with Fn14. The
superposition of the TWEAK structure and the NMR structure of
the Fn14 onto available experimentally determined structures of
related complexes resulted in a model that could be easily energy
minimized to remove any residual clashes and possesses a highly
complementary interface. In fact, the suggested specific hydrogen
bonding and ion pair network is consistent with mutational
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analysis and explains the unique formation of the TWEAK-Fn14
complex. Furthermore, the model is consistent with Fn14
trimerization, which is an integral part of TWEAK mediated
signaling.
Apart from TWEAK-mediated trimerization of Fn14, efficient
signaling is only achieved by Fn14 oligomerization [73]. Receptor
oligomerization is achieved either by membrane bound full length
TWEAK or, in analogy to other TNF superfamily members, by
binding of soluble TWEAK to HSPGs [13,65]. In contrast to the
specific interface between Fn14 and TWEAK, the identified basic
patch on the opposite side of the receptor binding region of soluble
TWEAK is likely to serve as a platform for binding to the
negatively charged HSPG, via electrostatically driven interactions.
Similarly, this positively charged surface is also found on related
cytokines such as APRIL and hence suggests that HSPG-mediated
stimulation of receptor oligomerization has related mechanisms in
different THD-CRD complexes [63,64].
In summary, we were able to obtain the first structural
information of soluble human TWEAK. The crystallization was
supported by the formation of a stable complex with the Fab
fragment of a neutralizing antibody. Based on the comparison of
the obtained TWEAK structure with published TNF ligand
receptor structures, we were able to model a putative TWEAK-
Fn14 complex. Furthermore, we identified a large positive surface
patch that is likely to serve as a binding platform for TWEAK to
negatively charged HSPG, thereby regulating the levels of
TWEAK. Taken together our findings provide the profound
molecular basis for future studies on the pleiotropic cytokine and
potential drug target TWEAK and its receptor Fn14.
Accession Number
Coordinates and structure factors for the crystal structure of
human TWEAK in complex with a therapeutic antibody Fab
Figure 4. Model of the TWEAK – Fn14 receptor interaction. A) Side view of the TWEAK trimer showing the solvent accessible electrostatic
surface potential (red 24 kT to blue +4 kT). The positively charged patch indicating the possible receptor binding site (dashed ellipse) is covered by
the antibody selected for inhibiting TWEAK-Fn14 interaction (cartoon model of Hv in green and Lv in blue). B) Same view as in A with the antibody
and TWEAK surface set transparence. After superposition of cytokine-receptor structures APRIL-BCMA (blue; PDB ID 1XU2), APRIL-TACI (brown; PDB ID
1XU1), TALL-BCMA (red; PDB ID 1OQD) and TALL-BAFFR (green; PDB ID 1OQE) the CRD of the receptors co-localize and mark the putative binding site
of Fn14 on TWEAK (only the CRD of the receptors is shown as colored cartoon model). C) The NMR model of the Fn14 CRD (blue; PDB ID 2RPJ) is
placed at the putative receptor binding site of TWEAK according to the complex structures shown in B. The basic patch is indicated with the dashed
ellipse. Only one of the three receptors is shown. D) Stereo view of the modeled TWEAK-Fn14 CRD interface. Upon rigid body and positional
refinement of the putative TWEAK-Fn14 CRD complex a dense hydrogen bond network is formed at the interface. The perfect complementarities of
charged and hydrophobic patches, as well as the involvement of Fn14 side chains already shown to play an important role in TWEAK binding support
this model.
doi:10.1371/journal.pone.0062697.g004
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fragment have been deposited in the Protein Data Bank with
accession code 4HT1.
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